Enfusion Long Term Debt

Enfusion posts a long-term debt of $14M as of December 2024. That compares with $11M in the prior-year period — up 27.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Enfusion's long-term debt was $11M. The latest reading is $14M — a 27.3% year-over-year increase (period ending December 2024). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Enfusion's financial statement story. At $14M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ENFN's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Enfusion's other metric pages and overview cover the third.

Judging Enfusion against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in long-term debt easier to interpret. Start with $14M here, then scan peer and history charts to see if the gap is persistent.